| Ytd | -3.01% | |
| 1y | 153.41% |
| Open | 23.22 | Prev Close | 22.99 | Low | 21.60 | High | 23.22 | Mkt Cap | 171.91M |
| Vol | 246.48K | Avg Vol | 133.85K | EPS | -23.99 | P/E | -0.96 | Forward P/E | -2.75 |
| Beta | 0.51 | Short Ratio | 0.97 | Inst. Own | 77.18% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-09 | 50-d Avg | 24.67 | 200-d Avg | 22.54 | 1yr Est | 33.00 |
SOUTH SAN FRANCISCO, Calif. , July 15, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "C
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Com
HC Wainwright & Co. analyst Matthew Caufield maintains Surrozen (NASDAQ:SRZN) with a Buy and
On track to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of
SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “C
Surrozen (NASDAQ: SRZN - Get Free Report) and MediWound (NASDAQ: MDWD - Get Free Report) are both sm
Surrozen (SRZN) saw its shares surge in the last session with trading volume being higher than avera
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Tcg Crossover Gp Ii, Llc acquired
HC Wainwright & Co. analyst Matthew Caufield reiterates Surrozen (NASDAQ:SRZN) with a Buy and
Surrozen (NASDAQ:SRZN) reported quarterly losses of $(20.13) per share which missed the analyst cons
Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Tcg Crossover Gp Ii, Llc acquired
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Co
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Co
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Surrozen (NASDAQ:SRZN) with a Ove
Surrozen (NASDAQ: SRZN - Get Free Report) and Galmed Pharmaceuticals (NASDAQ: GLMD - Get Free Report
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Co
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Group Gp Lp Column III bought 18,0
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Group Gp Lp Column III purchased 1
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) Director Tim Kutzkey purchased 11,893 shares of Surr
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) Director Tim Kutzkey purchased 18,052 shares of the
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) Director Tim Kutzkey acquired 5,523 shares of the bu
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Group Gp Lp Column III acquired 5,
Surrozen (NASDAQ:SRZN) reported quarterly losses of $(8.36) per share which missed the analyst conse
On October 14, 2025, Surrozen, Inc. (the "Company") received notice from TCGFB, Inc. ("T
Surrozen (NASDAQ:SRZN) reported quarterly earnings of $2.55 per share which beat the analyst consens
Newly granted patent is part of the expanding intellectual property portfolio directed to:-generatin
HC Wainwright & Co. analyst Matthew Caufield reiterates Surrozen (NASDAQ:SRZN) with a Buy and
Surrozen (NASDAQ:SRZN) reported quarterly losses of $(7.43) per share which missed the analyst conse
HC Wainwright & Co. analyst Matthew Caufield reiterates Surrozen (NASDAQ:SRZN) with a Buy and
Surrozen (NASDAQ:SRZN) reported quarterly losses of $(21.67) per share which missed the analyst cons
HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Surrozen (NASDAQ:SRZN) wit
Guggenheim analyst Yatin Suneja upgrades Surrozen (NASDAQ:SRZN) from Neutral to Buy and maintains
Surrozen (NASDAQ:SRZN) reported quarterly losses of $(0.44) per share which beat the analyst consens
Surrozen (NASDAQ:SRZN) reported quarterly losses of $(0.44) per share which beat the analyst consens
Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a company pioneering tar
On Wednesday, 340 stocks hit new 52-week lows.